{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-194427","form_type":"8-K","ticker":"KPTI","cik":"0001503802","company_name":"Karyopharm Therapeutics Inc.","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.281697+00:00","generated_at":"2026-05-31T12:14:26.001254+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Karyopharm Q2 revenue $42.8M, net income $23.8M on debt gain; raises FY guidance low end","bullets":["Q2 2024 total revenue $42.8M (Q2 2023: $37.6M); US XPOVIO net product revenue $28.0M (Q2 2023: $28.5M).","Net income $23.8M ($0.15 basic EPS) vs net loss $32.6M in Q2 2023; includes $44.7M non-cash gain on debt extinguishment.","Raises FY2024 total revenue guidance low end to $145M from $140M; lowers R&D/SG&A expense guidance to $250-265M from $260-280M.","Phase 3 SENTRY (myelofibrosis) top-line data on track for 2H 2025; XPORT-EC-042 (endometrial) top-line delayed to early 2026 due to screen failures.","Debt refinancing extended majority of maturities to 2028/2029; cash $152.5M; cash runway into Q1 2026 (excl. $49.5M debt payments)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-194427","json":"https://secwatch.observer/filing/0001193125-24-194427.json","markdown":"https://secwatch.observer/filing/0001193125-24-194427.md","text":"https://secwatch.observer/filing/0001193125-24-194427.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1503802/000119312524194427/0001193125-24-194427-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1503802/000119312524194427/d878101d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:14:26.001254+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}